Antigen-specific tolerance to self-antigens in protein replacement therapy, gene therapy and autoimmunity.
Antigen-specific tolerance to self-antigens in protein replacement therapy, gene therapy and autoimmunity.
Curr Opin Immunol. 2019 Aug 30;61:46-53
Authors: Steinman L, Ho PP, Robinson WH, Utz PJ, Villoslada P
Abstract
Trials of antigen-specific tolerance have been undertaken in the clinic for over fifty years and the results of these antigen-specific clinical trials are described in this review. Antigen-specific tolerization of the immune system in protein replacement therapy for hemophilia A is an accepted treatment. Clinical trials are ongoing for autoimmune conditions such as type 1 diabetes, multiple sclerosis, neuromyelitis optica, and rheumatoid arthritis with various antigen-specific strategies. Trials for tolerization in celiac disease aim for antigen specific tolerance to gluten, an environmental trigger, which may then halt the progression to autoimmunity targeting a self-antigen, tissue transglutaminase. Although many promising approaches have been demonstrated in pre-clinical models, this review will focus primarily on clinical trials of antigen-specific tolerance that have been taken to the clinic and with initial results reported in the peer reviewed literature. A separate article on approaches with CAR-T cells appears in this volume.
PMID: 31476445 [PubMed - as supplied by publisher]
Source: Current Opinion in Immunology - Category: Allergy & Immunology Authors: Steinman L, Ho PP, Robinson WH, Utz PJ, Villoslada P Tags: Curr Opin Immunol Source Type: research
More News: Allergy & Immunology | Arthritis | Autoimmune Disease | Brain | Celiac Disease | Clinical Trials | Coeliac Disease | Diabetes | Diabetes Type 1 | Endocrinology | Environmental Health | Gene Therapy | Genetics | Gluten | Haemophilia | Hemophilia | Multiple Sclerosis | Neurology | Rheumatoid Arthritis | Rheumatology